8月17日,复星医药(SH600196,股价24.01元,市值588.9亿元)公告披露,其控股子公司复宏汉霖与全球生物类似药龙头Sandoz AG于8月16日签订《合作框架协议》。 双方约定,可就复宏汉霖至多10款单克隆抗体(mAb)和/或抗体偶联药物(ADC)生物类似药,开展海外区域的注册、商业化、开发、生产等许可合作,并已就首批3款产品达成具体商业条款。 一次打包10款首期落定3款 据...
Source Link8月17日,复星医药(SH600196,股价24.01元,市值588.9亿元)公告披露,其控股子公司复宏汉霖与全球生物类似药龙头Sandoz AG于8月16日签订《合作框架协议》。 双方约定,可就复宏汉霖至多10款单克隆抗体(mAb)和/或抗体偶联药物(ADC)生物类似药,开展海外区域的注册、商业化、开发、生产等许可合作,并已就首批3款产品达成具体商业条款。 一次打包10款首期落定3款 据...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.